The INOvent delivery system is the first to gain FDA clearance for use in nitric oxide for inhalation therapy. Together with INOmax, the delivery sytem is expected to help critically ill infants brethe more effectively and to help reduce their need for an invasive surgical procedure known as ECMO (extracorporeal membrane oxygenation). The Inovent delivery system is CR-marked and has been available in selected EU and other countries since 1998 and is now available worldwide through Datex-Ohmeda's global sales network.
In North America, the INOvent delivery system will be available under exclusive license through INOTherapeutics. In order to ensure safe and effective delivery of the therapy, INO THerapeutics will provide it as part of a service that includes INOmax, the INOvent delivery system, equimpment maintenance and service and round-the-clock support for healthcare professionals. As part of their arrangment, INOTherapeutics and Detaex-Ohmeda are also developing new enhancements for the therapy.
The two companies anounced the alliance in December 1999. Ashleigh Palmer, President and CEO of INO Therapeutics, commented, "We are fortunate to have such a strong relationship already in place. The teams developed INOmax and the INOvent delivery system have work together for years to amke this important new therapy available to critically ill babies. Together we have the knowledge and expertise to support this pioneering theraoy." Lori Cross, Vice President and General Manager of Datex-Ohmeda's Anesthesia Delivery and Ventilation Business Area, said, "We are proud of our role in making this important new therapy available to clinicians. We have work closely with FDA and INO Therapeutics to help ensure that aur delivery system will set high standards for safe, precise delivery and monitoring." The INOvent delivery system delivers a constant concentration of nitric oxide for inhalation indepent of the ventilator being used and is designed to maintain critical delivery and monitoring functions under virtually all circumstances. In addition, the highly sensitive system monitors the exact amount of nitric oxide deliveres to the patient and shuts down automatically if the actual concentration exceeds the amount preset by the clinician. The INOvent delivery system is developed and manufactured at Datex-Ohmeda's Madison, Wisconsin facility. INOmax is a product of INO Therapeutics, Ins., a global health care company with expertise in critical care. The company, a subsidiary of the AGA Healthcare Division at AGA AB of Sweden, is headquartered inClinton, New Jersey. |
